Safety Data Committee approves recommended dose for LiPlaCis in Breast Cancer – recruitment satisfactory
Hoersholm, Denmark November 21st 2017 – Oncology Venture Sweden AB (OV:ST) announces today that the dose of 75mg + 75mg per patient on days 1 and 8 in a three weeks schedule was found safe and was approved by the data safety committee as the Recommended Dose (RD) for future treatments with LiPlaCis®. Furthermore, recruitment rate for the ongoing phase 2 part of the study of metastatic breast cancer patients in treatment with LiPlaCis has accelerated during the last couple of months and is satisfactory. Oncology Venture expects as previously announced to report on the progress of the